CSTLCastle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The compan…
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
Older | ||
 Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction Castle Biosciences (NASDAQ:CSTL) reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its reported beat, according to CFO Frank Stokes. Stokes said the company’s DecisionDx-Melanoma and TissueC | ||
 Castle Biosciences, Inc. Q2 2026 Earnings Call Summary Moby summary of Castle Biosciences, Inc.'s Q2 2026 earnings call | ||
Castle Biosciences Inc (CSTL) (Q2 2026) Earnings Call Highlights: Revenue Surges 20% to $103. ... Castle Biosciences raises 2026 revenue outlook to $365-$375M as TissueCypher volumes jump 63% and AdvanceAD-Tx secures favorable Medicare pricing. | ||
 Castle Biosciences Q2 Earnings Call Highlights Castle Biosciences (NASDAQ:CSTL) reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, as growth in its TissueCypher test and other core offerings supported results. The company raised its full-year revenue outlook to $365 million to $375 million, from a previous | ||
 Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates Castle Biosciences (CSTL) delivered earnings and revenue surprises of +84.09% and +18.61%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||